NEW ORLEANS--(BUSINESS WIRE)--Charles C. Foti, Jr., Esq., the former Attorney General of Louisiana, along with the law firm Kahn Swick & Foti, LLC (“KSF”), is looking into the planned sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. According to the deal, bluebird shareholders will receive $3.00 in cash for each share, plus a contingent value right that could provide an additional $6.84 in cash if certain conditions are met.
Bio-Rad plans to buy all shares of Stilla Technology. This purchase is anticipated to enhance Bio-Rad's current digital PCR offerings.
In the fourth quarter, Bio-Rad experienced growth in its Clinical Diagnostics segment, mainly due to a higher demand for quality control and blood typing products.
Bio-Rad Laboratories, Inc. (NYSE:BIO) will hold its Q4 2024 Earnings Conference Call on February 13, 2025, at 5:00 PM ET. The call will feature company representatives including Edward Chung, Jon DiVincenzo, Roop Lakkaraju, and Norman Schwartz, along with participants from various financial institutions. The operator for the call is Prila.
Bio-Rad Laboratories (BIO) reported quarterly earnings of $2.90 per share, which is lower than the Zacks Consensus Estimate of $2.93 per share. This is a decrease compared to earnings of $3.10 per share from the same period last year.
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a company in the clinical stage of developing new cancer treatments that are safer and more effective, has announced that it will take part in the 2025 BIO CEO & Investor Conference. This event will take place from February 10-11, 2025, at the New York Marriott Marquis.
Bio-Rad (BIO) may not have the right mix of factors needed for a strong earnings report in the near future. Be ready for the important expectations.
CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with both marketed products and a range of development candidates, has announced that its President and CEO, Dr. Seth Lederman, will speak at the BIO CEO & Investor Conference on February 10, 2025, at 1:45 p.m. ET in New York City.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a company focused on creating treatments for central nervous system, inflammatory, and cardiometabolic diseases, has announced that its Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will join a panel discussion at the 2025 BIO CEO & Investor Conference. This event is scheduled for February 10-11, 2025, in New York, NY.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a leading company in life science research and clinical diagnostics, will announce its financial results for the fourth quarter and the entire year of 2024 on Thursday, February 13, 2025, after the market closes. The management team will hold a conference call to discuss these results at 2 PM Pacific Time (5 PM Eastern Time) on the same day. To join the call, please dial (800) 715-9871 if you are in the U.S. or (646) 307-1963 if you are outside the U.S.